JPMorgan Chase & Co’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $98.8K | Buy |
19,533
+5,270
| +37% | +$26.7K | ﹤0.01% | 4801 |
|
|
2025
Q1 | $80.6K | Buy |
14,263
+3,837
| +37% | +$21.7K | ﹤0.01% | 4833 |
|
|
2024
Q4 | $90.5K | Buy |
10,426
+1,375
| +15% | +$11.9K | ﹤0.01% | 4814 |
|
|
2024
Q3 | $62.7K | Sell |
9,051
-10,307
| -53% | -$71.4K | ﹤0.01% | 4916 |
|
|
2024
Q2 | $120K | Buy |
19,358
+19,137
| +8,659% | +$119K | ﹤0.01% | 4518 |
|
|
2024
Q1 | $349 | Buy |
221
+12
| +6% | +$19 | ﹤0.01% | 5743 |
|
|
2023
Q4 | $307 | Buy |
209
+6
| +3% | +$9 | ﹤0.01% | 5967 |
|
|
2023
Q3 | $189 | Buy |
203
+17
| +9% | +$16 | ﹤0.01% | 5882 |
|
|
2023
Q2 | $234 | Hold |
186
| – | – | ﹤0.01% | 5713 |
|
|
2023
Q1 | $0 | Hold |
186
| – | – | ﹤0.01% | 5815 |
|
|
2022
Q4 | $0 | Sell |
186
-1,272
| -87% | – | ﹤0.01% | 5592 |
|
|
2022
Q3 | $5K | Buy |
1,458
+211
| +17% | +$724 | ﹤0.01% | 5181 |
|
|
2022
Q2 | $4K | Sell |
1,247
-2,140
| -63% | -$6.86K | ﹤0.01% | 5334 |
|
|
2022
Q1 | $17K | Buy |
3,387
+858
| +34% | +$4.31K | ﹤0.01% | 5292 |
|
|
2021
Q4 | $20K | Buy |
+2,529
| New | +$20K | ﹤0.01% | 5322 |
|